EGFR L858R

Clinical trials for EGFR L858R explained in plain language.

Never miss a new study

Get alerted when new EGFR L858R trials appear

Sign up with your email to follow new studies for EGFR L858R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 1

New combo shows promise for Hard-to-Treat lung cancer

Disease control Completed

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific genetic change (EGFR L858R). The goal was to see if this combo could delay cancer growth better than standard treatment. …

Matched conditions: EGFR L858R

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated Jun 27, 2026 09:07 UTC

EGFR L858R

Get alerted when new EGFR L858R trials appear

New combo shows promise for Hard-to-Treat lung cancer